Catalent, Inc.
(NYSE : CTLT)

( )
CTLT PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
MYOKMyoKardia, Inc. -0.02%222.401.8%$502.40m
HZNPHorizon Therapeutics Plc -0.05%74.275.8%$155.39m
VRXValeant Pharmaceuticals International, Inc. 3.29%17.5814.1%$103.44m
CTLTCatalent, Inc. -0.79%92.422.1%$84.83m
JAZZJazz Pharmaceuticals Plc -2.04%145.392.4%$82.09m
BHCBausch Health Cos., Inc. 3.29%17.580.0%$68.73m
ICLRICON plc -0.54%202.234.3%$48.88m
UTHRUnited Therapeutics Corp. -0.27%118.8514.1%$44.28m
ZGNXZogenix, Inc. 1.54%20.507.5%$42.04m
SAGESAGE Therapeutics, Inc. -4.03%67.258.6%$41.83m
ARGXargenx SE -2.19%256.800.0%$38.95m
ENDPEndo International Plc -5.69%5.478.7%$36.31m
AMRNAmarin Corp. Plc -3.28%4.721.5%$35.22m
PRGOPerrigo Co. Plc -2.82%44.866.8%$32.47m
GWPHGW Pharmaceuticals Plc 0.56%96.896.2%$29.96m

Company Profile

Catalent, Inc. operates as a holding company. The firm engages in the provision of delivery technologies and development solutions for drugs, biologics and consumer and animal health products. It operates through the following segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery and Clinical Supply Services. The Softgel Technologies segment formulates, develops and manufactures services for soft capsules. The Biologics and Specialty Drug Delivery segment develops and manufactures services for blow-fill-seal unit doses, prefilled syringes, vials and cartridges, analytical development and testing services for large molecules, inhaled products for delivery via metered dose inhalers, dry powder inhalers and intra-nasal sprays. The Oral Drug Delivery segment focuses in the formulation development and manufacturing technologies and related solutions including: clinical development and commercial manufacturing of a range of oral dose forms, including proprietary fast-dissolve Zydis tablets and both conventional immediate and controlled release tablets, capsules and sachet products. The Clinical Supply Services segment includes packaging, labeling, storage, distribution and inventory management for drugs and biologics in clinical trials. The company was founded in April 2007 and is headquartered in Somerset, NJ.